Enhance your nephrology practice with CME and tools focused on kidney medicine.
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Glasgow
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
June 04, 2026
Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
Ellie Kelepouris, MD, FACP, FAHA
Quantifying CKD-aP: Tools for Better Care
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
CKD-aP: Beyond the Surface
Leonie Kraft, MD
Is CKD-aP Hiding in Your Dialysis Center?
CKD-aP or Something Else? Decoding the Diagnosis
Precision Medicine in IgAN: A Deep Dive into Biomarkers, Evolving Guidelines, and Therapeutic Frontiers
Chee Kay Cheung, MBChB, PhD, FRCP
Raphael Duivenvoorden, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Nihar R. Desai, MD, MPH
Improving Sleep and Mental Health in Patients with CKD-aP
Lucio Manenti, MD, PhD
Elevating CKD-aP Care: New Frontier
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Patrick Rossignol, MD, PhD
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Potassium Binders in Practice: Clinical Trial Evidence
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Bernhard Hellmich, MD
Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
Thilo Krüger, MD, PhD
Steven Fishbane, MD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.